Harris JR, Morrow M, Bonadonna G. Cancer of the breast. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 4th ed. Philadelphia,
Pa: JB Lippincott Co; 1993:1264-1332.
Antman KH, Rowlings PA, Vaughan WP.
et al. High-dose chemotherapy with autologous hematopoietic stem-cell support
for breast cancer in North America. J Clin Oncol.1997;15:1870-1879.
Gradishar WJ, Tallman MS, Abrams JS. High-dose chemotherapy for breast cancer. Ann Intern Med.1996;125:599-604.
United States General Accounting Office. Report to the Honorable Ron Wyden, U.S. Senate: Health
Insurance: Coverage of Autologous Bone Marrow Transplantation for Breast Cancer. Gaithersburg, Md: US General Accounting Office; 1996. GAO/HEHS-96-83.
Peters WP, Rogers MC. Variation in approval by insurance companies of coverage for autologous
bone marrow transplantation for breast cancer. N Engl J Med.1994;330:473-477.
Peters WP, Shpall EJ, Jones RB.
et al. High-dose combination alkylating agents with bone marrow support as
initial treatment for metastatic breast cancer. J Clin Oncol.1988;6:1368-1376.
Williams SF, Mick R, Desser R, Golick J, Beschorner J, Bitran JD. High-dose consolidation therapy with autologous stem cell rescue in
stage IV breast cancer. J Clin Oncol.1989;7:1824-1830.
Dunphy FR, Spitzer G, Buzdar AU.
et al. Treatment of estrogen receptor–negative or hormonally refractory
breast cancer with double high-dose chemotherapy intensification and bone
marrow support. J Clin Oncol.1990;8:1207-1216.
Wallerstein Jr R, Spitzer G, Dunphy F.
et al. A phase II study of mitoxantrone, etoposide, and thiotepa with autologous
marrow support for patients with relapsed breast cancer. J Clin Oncol.1990;8:1782-1788.
Kennedy MJ, Beveridge RA, Rowley SD, Gordon GB, Abeloff MD, Davidson NE. High-dose chemotherapy with reinfusion of purged autologous bone marrow
following dose-intense induction as initial therapy for metastatic breast
cancer. J Natl Cancer Inst.1991;83:920-926.
Antman K, Ayash L, Elias A.
et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin
with autologous marrow support in women with measurable advanced breast cancer
responding to standard-dose therapy. J Clin Oncol.1992;10:102-110.
Ayash LJ, Elias A, Wheeler C.
et al. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood
progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol.1994;12:37-44.
Dunphy FR, Spitzer G, Fornoff JE.
et al. Factors predicting long-term survival for metastatic breast cancer
patients treated with high-dose chemotherapy and bone marrow support [published
correction appears in Cancer. 1994;74:773]. Cancer.1994;73:2157-2167.
Vaughan WP, Reed EC, Edwards B, Kessinger A. High-dose cyclophosphamide, thiotepa and hydroxyurea with autologous
hematopoietic stem cell rescue: an effective consolidation chemotherapy regimen
for early metastatic breast cancer. Bone Marrow Transplant.1994;13:619-624.
Ayash LJ, Wheeler C, Fairclough D.
et al. Prognostic factors for prolonged progression-free survival with high-dose
chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol.1995;13:2043-2049.
Weaver CH, West WH, Schwartzberg LS.
et al. Induction, mobilization of peripheral blood stem cells (PBSC), high-dose
chemotherapy and PBSC infusion in patients with untreated stage IV breast
cancer: outcomes by intent to treat analyses. Bone Marrow Transplant.1997;19:661-670.
Bensinger WI, Schiffman KS, Holmberg L.
et al. High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell
infusion for the treatment of metastatic breast cancer. Bone Marrow Transplant.1997;19:1183-1189.
Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment
for metastatic breast cancer: a randomized trial. J Clin Oncol.1995;13:2483-2489.
Kennedy MJ. High-dose chemotherapy of breast cancer: is the question answered [comment]? J Clin Oncol.1995;13:2477-2479.
Swenerton KD, Legha SS, Smith T.
et al. Prognostic factors in metastatic breast cancer treated with combination
chemotherapy. Cancer Res.1979;39:1552-1562.
Nash III CH, Jones SE, Moon TE, Davis SL, Salmon SE. Prediction of outcome in metastatic breast cancer treated with Adriamycin
combination chemotherapy. Cancer.1980;46:2380-2388.
Ahmann FR, Jones SE, Moon TE. The effect of prior adjuvant chemotherapy on survival in metastatic
breast cancer. J Surg Oncol.1988;37:116-122.
Falkson G, Gelman RS, Leone L, Falkson CI. Survival of premenopausal women with metastatic breast cancer: long-term
follow-up of Eastern Cooperative Group and Cancer and Leukemia Group B studies. Cancer.1990;66:1621-1629.
Falkson G, Gelman R, Falkson CI, Glick J, Harris J. Factors predicting for response, time to treatment failure, and survival
in women with metastatic breast cancer treated with DAVTH: a prospective Eastern
Cooperative Oncology Group study. J Clin Oncol.1991;9:2153-2161.
Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination
chemotherapy for metastatic breast cancer. J Clin Oncol.1996;14:2197-2205.
Henderson IC, Harris JR, Kinne DW, Hellman S. Cancer of the breast. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 3rd ed. Philadelphia,
Pa: JB Lippincott Co; 1989:1197-1268.
US Department of Health and Human Services, Public Health Service,
Centers for Disease Control and Prevention, National Center for Health Statistics. National Hospital Discharge Survey for 1990 and 1991. Hyattsville, Md: Hospital Care Statistics Branch, National Center
for Health Statistics. 1992.
Graves EJ. Detailed diagnoses and procedures, National Hospital Discharge Survey,
1989. Vital Health Stat 13.1991;108:1-236.
Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated
Data. New York, NY: Springer-Verlag; 1997.
Commenges D, Andersen PK. Score test of homogeneity for survival data. Lifetime Data Anal.1995;1:145-156.
Peters WP, Jones RB, Vredenburgh J.
et al. A large, prospective, randomized trial of high-dose combination alkylating
agents with autologous cellular support as consolidation for patients with
metastatic breast cancer achieving complete remission after intensive doxorubicin-based
induction therapy [abstract]. Proc Am Soc Clin Oncol.1996;15:121.
Rahman ZU, Frye DK, Buzdar AU.
et al. Impact of selection process on response rate and long-term survival
of potential high-dose chemotherapy candidates treated with standard-dose
doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol.1997;15:3171-3177.
Garcia-Carbonera R, Hidalgo M, Paz-Ares L.
et al. Patient selection in high-dose chemotherapy trials: relevance in high-risk
breast cancer. J Clin Oncol.1997;15:3178-3184.
Stadtmauer EA, O'Neil P, Goldstein LJ.
et al. Phase III randomized trial of high-dose chemotherapy (HDC) and stem
cell support (SCT) shows no difference in overall survival or severe toxicity
compared to maintenance chemotherapy with cyclophosphamide, methotrexate and
5-fluorouracil (CMF) for women with metastatic breast cancer who are responding
to conventional induction chemotherapy: the "Philadelphia" Intergroup Study
(PBT-1) [abstract]. Proc Am Soc Clin Oncol.1999;18:1a.